{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:11:32Z","timestamp":1788286292507,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tanner Project Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To compare the quantitative background parenchymal enhancement (BPE) in women with different lifetime risks and <jats:italic>BRCA<\/jats:italic> mutation status of breast cancer using screening MRI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>This study included screening MRI of 535 women divided into three groups based on lifetime risk: nonhigh-risk women, high-risk women without <jats:italic>BRCA<\/jats:italic> mutation, and <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers. Six quantitative BPE measurements, including percent enhancement (PE) and signal enhancement ratio (SER), were calculated on DCE-MRI after segmentation of the whole breast and fibroglandular tissue (FGT). The associations between lifetime risk factors and BPE were analyzed via linear regression analysis. We adjusted for risk factors influencing BPE using propensity score matching (PSM) and compared the BPE between different groups. A two-sided Mann\u2013Whitney U-test was used to compare the BPE with a threshold of 0.1 for multiple testing issue-adjusted <jats:italic>p<\/jats:italic> values.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Age, BMI, menopausal status, and FGT level were significantly correlated with quantitative BPE based on the univariate and multivariable linear regression analyses. After adjusting for age, BMI, menopausal status, hormonal treatment history, and FGT level using PSM, significant differences were observed between high-risk non-<jats:italic>BRCA<\/jats:italic> and <jats:italic>BRCA<\/jats:italic> groups in PE<jats:sub>FGT<\/jats:sub> (11.5 vs. 8.0%, adjusted <jats:italic>p<\/jats:italic>\u2009=\u20090.018) and SER<jats:sub>FGT<\/jats:sub> (7.2 vs. 9.3%, adjusted <jats:italic>p<\/jats:italic>\u2009=\u20090.066).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Quantitative BPE varies in women with different lifetime breast cancer risks and <jats:italic>BRCA<\/jats:italic> mutation status. These differences may be due to the influence of multiple lifetime risk factors. Quantitative BPE differences remained between groups with and without <jats:italic>BRCA<\/jats:italic> mutations after adjusting for known risk factors associated with BPE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical relevance statement<\/jats:title>\n                <jats:p><jats:italic>BRCA<\/jats:italic> germline mutations may be associated with quantitative background parenchymal enhancement, excluding the effects of known confounding factors. This finding can provide potential insights into the cancer pathophysiological mechanisms behind lifetime risk models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p><jats:italic>Expanding understanding of breast cancer pathophysiology allows for improved risk stratification and optimized screening protocols.<\/jats:italic><\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p><jats:italic>Quantitative BPE is significantly associated with lifetime risk factors and differs between BRCA mutation carriers and noncarriers.<\/jats:italic><\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p><jats:italic>This research offers a possible understanding of the physiological mechanisms underlying quantitative BPE and BRCA germline mutations.<\/jats:italic><\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-024-10758-9","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T07:02:22Z","timestamp":1714374142000},"page":"6358-6368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-8654","authenticated-orcid":false,"given":"Ran","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-I.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lee-Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5322","authenticated-orcid":false,"given":"Kyunghyun","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"10758_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"10758_CR2","first-page":"60","volume":"10","author":"A Hunter","year":"2007","unstructured":"Hunter A (2007) Mammographic density: the risk and detection of breast caner. J BioLaw Bus 10:60\u201361","journal-title":"J BioLaw Bus"},{"key":"10758_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","volume":"57","author":"D Saslow","year":"2007","unstructured":"Saslow D, Boetes C, Burke W et al (2007) American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75\u201389","journal-title":"CA Cancer J Clin"},{"key":"10758_CR4","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1200\/JCO.2017.35.15_suppl.1508","volume":"35","author":"MS Bae","year":"2017","unstructured":"Bae MS, Sung JS, Han W et al (2017) Survival outcomes of screening with breast MRI in high-risk women. J Clin Oncol 35:1508\u20131508","journal-title":"J Clin Oncol"},{"key":"10758_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879\u20131886","journal-title":"J Natl Cancer Inst"},{"key":"10758_CR6","first-page":"232","volume":"48","author":"EB Claus","year":"1991","unstructured":"Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232\u2013242","journal-title":"Am J Hum Genet"},{"key":"10758_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111\u20131130","journal-title":"Stat Med"},{"key":"10758_CR8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djq088","volume":"102","author":"E Amir","year":"2010","unstructured":"Amir E, Freedman OC, Seruga B, Evans DG (2010) Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 102:680\u2013691","journal-title":"J Natl Cancer Inst"},{"key":"10758_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jnci\/djp018","volume":"101","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Tice JA, Bauer S et al (2009) Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 101:384\u2013398","journal-title":"J Natl Cancer Inst"},{"key":"10758_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/jmg.40.11.807","volume":"40","author":"E Amir","year":"2003","unstructured":"Amir E, Evans DG, Shenton A et al (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40:807\u2013814","journal-title":"J Med Genet"},{"key":"10758_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1148\/radiol.11102156","volume":"260","author":"V King","year":"2011","unstructured":"King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260:50\u201360","journal-title":"Radiology"},{"key":"10758_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1148\/radiol.2015142304","volume":"276","author":"BN Dontchos","year":"2015","unstructured":"Dontchos BN, Rahbar H, Partridge SC et al (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276:371\u2013380","journal-title":"Radiology"},{"key":"10758_CR13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.2214\/AJR.18.20566","volume":"212","author":"DA Sippo","year":"2019","unstructured":"Sippo DA, Rutledge GM, Burk KS et al (2019) Effect of background parenchymal enhancement on cancer risk across different high-risk patient populations undergoing screening breast MRI. AJR Am J Roentgenol 212:1412\u20131418","journal-title":"AJR Am J Roentgenol"},{"key":"10758_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/jmri.26636","volume":"50","author":"A Saha","year":"2019","unstructured":"Saha A, Grimm LJ, Ghate SV et al (2019) Machine learning-based prediction of future breast cancer using algorithmically measured background parenchymal enhancement on high-risk screening MRI. J Magn Reson Imaging 50:456\u2013464","journal-title":"J Magn Reson Imaging"},{"key":"10758_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2214\/AJR.20.23804","volume":"217","author":"BL Niell","year":"2021","unstructured":"Niell BL, Abdalah M, Stringfield O et al (2021) Quantitative measures of background parenchymal enhancement predict breast cancer risk. AJR Am J Roentgenol 217:64\u201375","journal-title":"AJR Am J Roentgenol"},{"key":"10758_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1148\/radiol.2019182441","volume":"292","author":"CM Thompson","year":"2019","unstructured":"Thompson CM, Mallawaarachchi I, Dwivedi DK et al (2019) The association of background parenchymal enhancement at breast mri with breast cancer: a systematic review and meta-analysis. Radiology 292:552\u2013561","journal-title":"Radiology"},{"key":"10758_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jmri.26762","volume":"51","author":"GJ Liao","year":"2020","unstructured":"Liao GJ, Henze Bancroft LC, Strigel RM et al (2020) Background parenchymal enhancement on breast MRI: a comprehensive review. J Magn Reson Imaging 51:43\u201361","journal-title":"J Magn Reson Imaging"},{"key":"10758_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.acra.2015.11.011","volume":"23","author":"AA Lewin","year":"2016","unstructured":"Lewin AA, Gene Kim S, Babb JS et al (2016) Assessment of background parenchymal enhancement and lesion kinetics in breast MRI of BRCA 1\/2 mutation carriers compared to matched controls using quantitative kinetic analysis. Acad Radiol 23:358\u2013367","journal-title":"Acad Radiol"},{"key":"10758_CR19","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402\u20132416","journal-title":"JAMA"},{"key":"10758_CR20","doi-asserted-by":"crossref","unstructured":"Murakami W, Mortazavi S, Yu T et al (2023) Clinical significance of background parenchymal enhancement in breast cancer risk stratification. J Magn Reson Imaging 59:1742\u20131757","DOI":"10.1002\/jmri.29015"},{"key":"10758_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinimag.2018.06.010","volume":"51","author":"A Grubstein","year":"2018","unstructured":"Grubstein A, Rapson Y, Benzaquen O et al (2018) Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance imaging between BRCA gene mutation carriers and non-carriers. Clin Imaging 51:347\u2013351","journal-title":"Clin Imaging"},{"key":"10758_CR22","first-page":"1","volume":"1","author":"R Goodburn","year":"2023","unstructured":"Goodburn R, Kousi E, Sanders C et al (2023) Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: association with BRCA status. Eur Radiol 1:1\u20139","journal-title":"Eur Radiol"},{"key":"10758_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/ijc.31370","volume":"143","author":"JD Brooks","year":"2018","unstructured":"Brooks JD, Sung JS, Pike MC et al (2018) MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women. Int J Cancer 143:823\u2013830","journal-title":"Int J Cancer"},{"key":"10758_CR24","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s00330-012-2553-8","volume":"22","author":"V King","year":"2012","unstructured":"King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA (2012) Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 22:2641\u20132647","journal-title":"Eur Radiol"},{"key":"10758_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1148\/radiol.13121101","volume":"268","author":"AR Amarosa","year":"2013","unstructured":"Amarosa AR, McKellop J, Leite APK et al (2013) Evaluation of the kinetic properties of background parenchymal enhancement throughout the phases of the menstrual cycle. Radiology 268:356\u2013365","journal-title":"Radiology"},{"key":"10758_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/mp.12079","volume":"44","author":"MU Dalmi\u015f","year":"2017","unstructured":"Dalmi\u015f MU, Litjens G, Holland K et al (2017) Using deep learning to segment breast and fibroglandular tissue in MRI volumes. Med Phys 44:533\u2013546","journal-title":"Med Phys"},{"key":"10758_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1109\/TMI.2010.2046908","volume":"29","author":"NJ Tustison","year":"2010","unstructured":"Tustison NJ, Avants BB, Cook PA et al (2010) N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 29:1310\u20131320","journal-title":"IEEE Trans Med Imaging"},{"key":"10758_CR28","doi-asserted-by":"crossref","unstructured":"Wu S, Weinstein SP, DeLeo MJ et al (2015) Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1\/2 mutation carriers. Breast Cancer Res 19:67","DOI":"10.1186\/s13058-015-0651-7"},{"key":"10758_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0734-0","volume":"18","author":"S Wu","year":"2016","unstructured":"Wu S, Berg WA, Zuley ML et al (2016) Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Res 18:76","journal-title":"Breast Cancer Res"},{"key":"10758_CR30","doi-asserted-by":"publisher","first-page":"531.e1","DOI":"10.1016\/j.urolonc.2019.03.017","volume":"37","author":"M Deebajah","year":"2019","unstructured":"Deebajah M, Keeley J, Park H et al (2019) A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate. Urol Oncol 37:531.e1\u2013531.e5","journal-title":"Urol Oncol"},{"key":"10758_CR31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1177\/0284185120911583","volume":"61","author":"R Hellgren","year":"2020","unstructured":"Hellgren R, Saracco A, Strand F et al (2020) The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI. Acta Radiol 61:1600\u20131607","journal-title":"Acta Radiol"},{"key":"10758_CR32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.clinimag.2016.08.009","volume":"40","author":"J Gillman","year":"2016","unstructured":"Gillman J, Chun J, Schwartz S, Schnabel F, Moy L (2016) The relationship of obesity, mammographic breast density, and magnetic resonance imaging in patients with breast cancer. Clin Imaging 40:1167\u20131172","journal-title":"Clin Imaging"},{"key":"10758_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894020952023","volume":"10","author":"KM Mair","year":"2020","unstructured":"Mair KM, Gaw R, MacLean MR (2020) Obesity, estrogens and adipose tissue dysfunction \u2013 implications for pulmonary arterial hypertension. Pulm Circ 10:1\u201321","journal-title":"Pulm Circ"},{"key":"10758_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2214\/AJR.10.4550","volume":"196","author":"NM Hambly","year":"2011","unstructured":"Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA (2011) Background parenchymal enhancement on baseline screening breast MRI: Impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol 196:218\u2013224","journal-title":"AJR Am J Roentgenol"},{"key":"10758_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ejrad.2011.04.059","volume":"81","author":"T Uematsu","year":"2012","unstructured":"Uematsu T, Kasami M, Watanabe J (2012) Should breast MRI be performed with adjustment for the phase in patients\u2019 menstrual cycle? Correlation between mammographic density, age, and background enhancement on breast MRI without adjusting for the phase in patients\u2019 menstrual cycle. Eur J Radiol 81:1539\u20131542","journal-title":"Eur J Radiol"},{"key":"10758_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13058-020-01375-7","volume":"22","author":"GP Watt","year":"2020","unstructured":"Watt GP, Sung J, Morris EA et al (2020) Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Res 22:138","journal-title":"Breast Cancer Res"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10758-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10758-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10758-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T17:19:00Z","timestamp":1726247940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10758-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["10758"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10758-9","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is one of the authors, Kyunghyun Sung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors, Fang-I Chu, has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The Institutional Review Board of the University of California (Los Angeles) approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}